Novel Hypoglycaemic Agents: Considerations in Patients with Chronic Kidney Disease

Publisher： Karger

E-ISSN： 1660-2110|126|1|14-18

ISSN： 1660-2110

Source： Nephron Clin Pract, Vol.126, Iss.1, 2014-01, pp. : 14-18

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Metformin: The Safest Hypoglycaemic Agent in Chronic Kidney Disease?

By  

Nephron Clin Pract, Vol. 118, Iss. 4, 2011-02 ,pp. : c380-c383

Karger

Access to resources Recommend Favorite

Anemia treatment with Q2W darbepoetin alfa in patients with chronic kidney disease naïve to erythropoiesis-stimulating agents*

By Silver M. R.   Geronemus R.   Krause M.   Chen C. Y.   Kewalramani R.   Stehman-Breen C.  

Current Medical Research and Opinion, Vol. 25, Iss. 1, 2009-01 ,pp. : 123-131

Informa Healthcare

Access to resources Recommend Favorite

Dosing patterns, hematologic outcomes, and costs of erythropoietic agents in predialysis chronic kidney disease patients with anemia

By Papatheofanis Frank J.   McKenzie R. Scott   Mody Samir H.   Suruki Robert Y.   Piech Catherine Tak  

Current Medical Research and Opinion, Vol. 22, Iss. 5, 2006-05 ,pp. : 837-842

Informa Healthcare

Access to resources Recommend Favorite

The prevalence of anemia in patients with chronic kidney disease

By McClellan William   Aronoff Stephen L.   Bolton W. Kline   Hood Sally   Lorber Daniel L.   Tang K. Linda   Tse Thomas F.   Wasserman Brian   Leiserowitz Marc  

Current Medical Research and Opinion, Vol. 20, Iss. 9, 2004-09 ,pp. : 1501-1510

Informa Healthcare

Access to resources Recommend Favorite

Statins in patients with chronic kidney disease – an attempt at recommendations

By Banach Maciej    

Current Medical Research and Opinion, Vol. 29, Iss. 11, 2013-11 ,pp. : 1419-1422

Informa Healthcare

Access to resources Recommend Favorite